Aquestive Therapeutics Stock Forecast
Recent Aquestive Therapeutics Stock Price |
|
Aquestive Therapeutics Stock Forecast Price |
$3.09 |
+205.18% |
$9.43 |
As of 2024-05-13
Recent Aquestive Therapeutics Analyst Ratings Breakdown |
|
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
Strong buy ratings: |
7 |
6 |
5 |
4 |
Buy ratings: |
1 |
1 |
0 |
0 |
Hold ratings: |
0 |
0 |
0 |
0 |
Sell ratings: |
0 |
0 |
0 |
0 |
Strong sell ratings: |
0 |
0 |
0 |
0 |
Average rating: |
1.13 |
1.14 |
1.0 |
1.0 |
In the last row of the above table, the average rating presented is from 1 to 5 where 1 means Strong Buy and 5 means Strong Sell.
The presented Aquestive Therapeutics stock forecast (traded under symbol AQST), for forward-twelve-months price target as shown at the top of this page, gives you the average Aquestive Therapeutics stock forecast for forward target price for symbol AQST, across the 7 analysts covering Aquestive Therapeutics (AQST), as reported in
data provided by Zacks Investment Research via Quandl.com.
Investors should also take note that the median Aquestive Therapeutics stock forecast price target (i.e. representing the middle ground number where half of analysts had a higher Aquestive Therapeutics stock forecast and half had a lower Aquestive Therapeutics stock forecast) was $9.0 as of 2024-05-13 (which is a different mathematical metric versus taking the average or mean), while the
highest Aquestive Therapeutics stock forecast in the analyst group was $13.0, and the lowest Aquestive Therapeutics stock forecast in the analyst group was
$7.0, with a standard deviation of $1.902. Get the latest Zacks research report on AQST — FREE
Top Analyst Picks of the Dow
The Top 20 Largest U.S. Stocks By Market Cap
Company Name: |
Aquestive Therapeutics Inc |
Website: |
www.aquestive.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding AQST: |
5 |
Total Market Value Held by ETFs: |
$13.23M |
Total Market Capitalization: |
$300.00M |
% of Market Cap. Held by ETFs: |
4.41% |
|
|
May 13, 2024 10:33 PM Eastern
Strong Buy (3.87 out of 4)
75th percentile
|
|